ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. **NAME OF THE MEDICINAL PRODUCT**

Piqray 50 mg film-coated tablets
Piqray 150 mg film-coated tablets
Piqray 200 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Piqray 50 mg film-coated tablets
Each film-coated tablet contains 50 mg of alpelisib.

Piqray 150 mg film-coated tablets
Each film-coated tablet contains 150 mg of alpelisib.

Piqray 200 mg film-coated tablets
Each film-coated tablet contains 200 mg of alpelisib.

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Film-coated tablet (tablet).

Piqray 50 mg film-coated tablets
Light pink, round, curved film-coated tablet with bevelled edges, imprinted with “L7” on one side and “NVR” on the other side. Approximate diameter: 7.2 mm.

Piqray 150 mg film-coated tablets
Pale red, ovaloid, curved film-coated tablet with bevelled edges, imprinted with “UL7” on one side and “NVR” on the other side. Approximate size: 14.2 mm (length); 5.7 mm (width).

Piqray 200 mg film-coated tablets
Light red, ovaloid, curved film-coated tablet with bevelled edges, imprinted with “YL7” on one side and “NVR” on the other side. Approximate size: 16.2 mm (length); 6.5 mm (width).

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1).
4.2 Posology and method of administration

Treatment with Piqray should be initiated by a physician experienced in the use of anticancer therapies.

Patients with HR-positive, HER2-negative advanced breast cancer should be selected for treatment with Piqray based on the presence of a PIK3CA mutation in tumour or plasma specimens, using a validated test. If a mutation is not detected in a plasma specimen, tumour tissue should be tested if available.

Posology

The recommended dose is 300 mg alpelisib (2x 150 mg film-coated tablets) taken once daily on a continuous basis. Piqray should be taken immediately after food, at approximately the same time each day (see section 5.2). The maximum recommended daily dose of Piqray is 300 mg.

If a dose of Piqray is missed, it can be taken immediately following food and within 9 hours after the time it is usually administered. After more than 9 hours, the dose should be skipped for that day. On the next day, Piqray should be taken at the usual time. If the patient vomits after taking the Piqray dose, the patient should not take an additional dose on that day and should resume the usual dosing schedule the next day at the usual time.

Piqray should be co-administered with fulvestrant. The recommended dose of fulvestrant is 500 mg administered intramuscularly on days 1, 15 and 29, and once monthly thereafter. Please refer to the full prescribing information of fulvestrant.

Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs. Dose modifications may be necessary to improve tolerability.

Dose modifications

Management of severe or intolerable adverse drug reactions (ADRs) may require temporary dose interruption, reduction, and/or discontinuation of Piqray. If dose reduction is required, the dose reduction guidelines for ADRs are listed in Table 1. A maximum of 2 dose reductions are recommended, after which the patient should be permanently discontinued from treatment with Piqray. Dose reduction should be based on the worst preceding toxicity.

Table 1: Recommended dose reduction guidelines for ADRs for Piqray

<table>
<thead>
<tr>
<th>Piqray dose level</th>
<th>Dose and schedule</th>
<th>Number and strength of tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting dose</td>
<td>300 mg/day continuously</td>
<td>2x 150 mg tablets</td>
</tr>
<tr>
<td>First dose reduction</td>
<td>250 mg/day continuously</td>
<td>1x 200 mg tablet and 1x 50 mg tablet</td>
</tr>
<tr>
<td>Second dose reduction</td>
<td>200 mg/day continuously</td>
<td>1x 200 mg tablet</td>
</tr>
</tbody>
</table>

1 Only one dose reduction is permitted for pancreatitis.

Tables 2-5 summarise the recommendations for dose interruption, reduction or discontinuation of Piqray in the management of specific ADRs. The clinical judgement of the treating physician, including confirmation of laboratory values if deemed necessary, should guide the management plan of each patient based on the individual benefit/risk assessment for treatment with Piqray.

Hyperglycaemia

Consultation with a healthcare professional experienced in the treatment of hyperglycaemia should always be considered and is recommended for patients who are pre-diabetic or those with fasting glucose (FG) >250 mg/dl or 13.9 mmol/l, body mass index (BMI) ≥30 or age ≥75 years.

Consultation with a diabetologist or a healthcare professional experienced in the treatment of hyperglycaemia should always take place for patients with diabetes.
<table>
<thead>
<tr>
<th>Fasting glucose (FG) values</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose modification and management should only be based on fasting glucose (plasma/blood) values.</td>
<td></td>
</tr>
<tr>
<td>&gt;ULN-160 mg/dl or &gt;ULN-8.9 mmol/l</td>
<td>No Piqray dose adjustment required. Initiate or intensify oral antidiabetic treatment.</td>
</tr>
<tr>
<td>&gt;160-250 mg/dl or &gt;8.9-13.9 mmol/l</td>
<td>No Piqray dose adjustment required. Initiate or intensify oral antidiabetic treatment. If FG does not decrease to ≤160 mg/dl or 8.9 mmol/l within 21 days with appropriate oral antidiabetic treatment, reduce Piqray dose by 1 level and follow FG-value-specific recommendations.</td>
</tr>
<tr>
<td>&gt;250-500 mg/dl or &gt;13.9-27.8 mmol/l</td>
<td>Interrupt Piqray. Initiate or intensify oral antidiabetic treatment and consider additional antidiabetic medicinal products such as insulin for 1-2 days until hyperglycaemia resolves, as clinically indicated. Administer intravenous hydration and consider appropriate treatment (e.g. intervention for electrolyte / ketoacidosis / hyperosmolar disturbances). If FG decreases to ≤160 mg/dl or 8.9 mmol/l within 3 to 5 days under appropriate antidiabetic treatment, resume Piqray at next lower dose level. If FG does not decrease to ≤160 mg/dl or 8.9 mmol/l within 3 to 5 days under appropriate antidiabetic treatment, consultation with a healthcare professional with expertise in the treatment of hyperglycaemia is recommended. If FG does not decrease to ≤160 mg/dl or 8.9 mmol/l within 21 days following appropriate antidiabetic treatment, permanently discontinue Piqray treatment.</td>
</tr>
<tr>
<td>&gt;500 mg/dl or &gt;27.8 mmol/l</td>
<td>Interrupt Piqray. Initiate or intensify appropriate antidiabetic treatment (administer intravenous hydration and consider appropriate treatment [e.g. intervention for electrolyte / ketoacidosis / hyperosmolar disturbances], re-check within 24 hours and as clinically indicated. If FG decreases to ≤500 mg/dl or ≤27.8 mmol/l, then follow FG-value-specific recommendations for &lt;500 mg/dl. If FG is confirmed at &gt;500 mg/dl or &gt;27.8 mmol/l after 24 hours, permanently discontinue Piqray treatment.</td>
</tr>
</tbody>
</table>

1 Fasting glucose levels reflect hyperglycaemia grading according to CTCAE Version 4.03 CTCAE = Common Terminology Criteria for Adverse Events.
2 Applicable antidiabetic medicinal products, such as metformin, SGLT2 inhibitors or insulin sensitisers (such as thiazolidinediones or dipeptidyl peptidase-4 inhibitors), should be initiated and the respective prescribing information should be reviewed for dosing and dose titration recommendations, including local diabetic treatment guidelines. Metformin was recommended in the phase III clinical study with the following guidance: Metformin should be initiated at 500 mg once daily. Based on tolerability, the metformin dose may be increased to 500 mg twice daily, followed by 500 mg with breakfast, and 1000 mg with the evening meal, followed by further increase to 1000 mg twice daily if needed (see section 4.4). As recommended in the phase III clinical study, insulin may be used for 1-2 days until hyperglycaemia resolves. However, this may not be necessary in the majority of cases of alpelisib-induced hyperglycaemia, given the short half-life of alpelisib and the expectation that glucose levels will normalise following interruption of Piqray.
Baseline diabetic and pre-diabetic status, baseline BMI ≥30 and baseline age ≥75 years have been found to be risk factors for hyperglycaemia in patients treated with alpelisib. These risk factors were present in 74.7% of patients with any grade of hyperglycaemia and in 86.2% of patients with grade 3 or 4 hyperglycaemia (see section 4.4).

Rash
Oral antihistamine administration may be considered prophylactically, at the time of initiation of treatment with Piqray. Additionally, antihistamines are recommended to manage symptoms of rash.

Topical corticosteroid treatment should be initiated at the first signs of rash and systemic corticosteroids should be considered for moderate to severe rashes. Based on the severity of rash, Piqray may require dose interruption, reduction or discontinuation as described in Table 3 (see section 4.8).

Table 3  Dose modification and management for rash

<table>
<thead>
<tr>
<th>Grade1</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>All grades</td>
<td>Consultation with a dermatologist should always be considered.</td>
</tr>
<tr>
<td>Grade 1 (&lt;10% body surface area [BSA] with active skin toxicity)</td>
<td>No Piqray dose adjustment required. Initiate topical corticosteroid treatment. Consider adding oral antihistamine treatment to manage symptoms. If active rash is not improved within 28 days of appropriate treatment, add a low dose systemic corticosteroid.</td>
</tr>
<tr>
<td>Grade 2 (10-30% BSA with active skin toxicity)</td>
<td>No Piqray dose adjustment required. Initiate or intensify topical corticosteroid and oral antihistamine treatment. Consider low-dose systemic corticosteroid treatment. If rash improves to grade ≤1 within 10 days, systemic corticosteroid may be discontinued.</td>
</tr>
<tr>
<td>Grade 3 (e.g. severe rash not responsive to medical management) (&gt;30% BSA with active skin toxicity)</td>
<td>Interrupt Piqray until rash improves to grade ≤1. Initiate or intensify topical/systemic corticosteroid and antihistamine treatment. Once rash improves to grade ≤1, resume Piqray at next lower dose level.</td>
</tr>
<tr>
<td>Grade 4 (e.g. severe bullous, blistering or exfoliating skin conditions) (any % BSA associated with extensive superinfection, with intravenous antibiotics indicated; life-threatening consequences)</td>
<td>Permanently discontinue Piqray.</td>
</tr>
</tbody>
</table>

1 Grading according to CTCAE Version 5.0
Diarrhoea or colitis

Table 4 Dose modification and management for diarrhoea or colitis

<table>
<thead>
<tr>
<th>Grade</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>No Piqray dose adjustment is required. Initiate appropriate medical therapy and monitor as clinically indicated.</td>
</tr>
<tr>
<td>Grade 2&lt;sup&gt;2&lt;/sup&gt;</td>
<td>Interrupt Piqray dose. Initiate or intensify appropriate medical therapy and monitor as clinically indicated. If diarrhoea or colitis improves to grade ≤1, then resume Piqray at same dose level. For recurrent diarrhoea or colitis grade ≥2, interrupt Piqray dose until improvement to grade ≤1, then resume Piqray at the next lower dose level.</td>
</tr>
<tr>
<td>Grade 3&lt;sup&gt;2,3&lt;/sup&gt;</td>
<td>Interrupt Piqray dose. Initiate or intensify appropriate medical therapy and monitor as clinically indicated. If diarrhoea or colitis improves to grade ≤1, then resume Piqray at the next lower dose level.</td>
</tr>
<tr>
<td>Grade 4&lt;sup&gt;2,3&lt;/sup&gt;</td>
<td>Permanently discontinue Piqray.</td>
</tr>
</tbody>
</table>

1 Grading according to CTCAE Version 5.0.
2 For grade ≥2 consider additional treatment, such as steroids.
3 Patients should additionally be managed according to local standard of care, including electrolyte monitoring, administration of antiemetics and antidiarrhoeal medicinal products and/or fluid replacement and electrolyte supplements, as clinically indicated.

Other toxicities

Table 5 Dose modification and management for other toxicities (excluding hyperglycaemia, rash and diarrhoea or colitis)

<table>
<thead>
<tr>
<th>Grade</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1 or 2</td>
<td>No Piqray dose adjustment required. Initiate appropriate medical therapy and monitor as clinically indicated&lt;sup&gt;2,3&lt;/sup&gt;.</td>
</tr>
<tr>
<td>Grade 3</td>
<td>Interrupt Piqray dose until improvement to grade ≤1, then resume Piqray at the next lower dose level&lt;sup&gt;2&lt;/sup&gt;.</td>
</tr>
<tr>
<td>Grade 4</td>
<td>Permanently discontinue Piqray&lt;sup&gt;3&lt;/sup&gt;.</td>
</tr>
</tbody>
</table>

1 Grading according to CTCAE Version 5.0
2 For grade 2 and 3 pancreatitis, interrupt Piqray dose until improvement to grade ≤1 and resume at next lower dose level. Only one dose reduction is permitted. If toxicity recurs, permanently discontinue Piqray treatment.
3 For grade 2 total bilirubin elevation, interrupt Piqray dose until recovery to grade ≤1 and resume at the same dose if resolved in ≤14 days or resume at the next lower dose level if resolved in >14 days.

Special populations

Elderly
No dose regimen adjustment is required in patients aged 65 years or above (see section 5.2). There are limited data in patients aged ≥75 years, and especially for those ≥85 years.

Renal impairment
Based on population pharmacokinetic analysis, no dose adjustment is necessary in patients with mild or moderate renal impairment (see section 5.2). Caution should be used in patients with severe renal impairment as there is no experience with Piqray in this population.

Hepatic impairment
Based on a hepatic impairment study in non-cancer subjects with impaired hepatic function, no dose adjustment is necessary in patients with mild, moderate or severe hepatic impairment (Child-Pugh class A, B or C, respectively) (see section 5.2).
Paediatric population
The safety and efficacy of Piqray in children aged 0-18 years have not been established. No data are available.

Method of administration
Piqray is for oral use. The tablets should be swallowed whole. They should not be chewed, crushed or split prior to swallowing. Tablets that are broken, cracked or otherwise not intact should not be ingested.

4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use
Fulvestrant
Due to limited data in patients with prior fulvestrant use (n=39, study CBYL719X2101), efficacy is not considered established in this population (see section 5.1).

Hypersensitivity (including anaphylactic reaction)
Serious hypersensitivity reactions (including anaphylactic reaction, anaphylactic shock and angioedema), manifested by symptoms including, but not limited to, dyspnoea, flushing, rash, fever or tachycardia, were reported in patients treated with Piqray (see section 4.8). Piqray should be permanently discontinued and should not be re-introduced in patients with serious hypersensitivity reactions. Appropriate treatment should be promptly initiated.

Severe cutaneous reactions
Severe cutaneous reactions have been reported with alpelisib. In the phase III clinical study, Stevens-Johnson syndrome (SJS) and erythema multiforme (EM) were reported in 1 (0.4%) and 3 (1.1%) patients, respectively. Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in the post-marketing setting (see section 4.8).

Piqray treatment should not be initiated in patients with a history of severe cutaneous reactions.

Patients should be advised of the signs and symptoms of severe cutaneous reactions (e.g. a prodrome of fever, flu-like symptoms, mucosal lesions or progressive skin rash). If signs or symptoms of severe cutaneous reactions are present, Piqray should be interrupted until the aetiology of the reaction has been determined. A consultation with a dermatologist is recommended.

If a severe cutaneous reaction is confirmed, Piqray should be permanently discontinued. Piqray should not be re-introduced in patients who have experienced previous severe cutaneous reactions. If a severe cutaneous reaction is not confirmed, Piqray may require treatment interruption, dose reduction or treatment discontinuation as described in Table 3 (see section 4.2).

Hyperglycaemia
Severe hyperglycaemia, in some cases associated with hyperglycaemic hyperosmolar nonketotic syndrome (HHNKS) or ketoacidosis, has been observed in patients treated with Piqray. Some cases of ketoacidosis with fatal outcome have been reported in the post-marketing setting.
In the phase III clinical study, hyperglycaemia occurred more frequently in patients who were diabetic (0 out of 12 patients [0%] with grade 1-2, and 10 out of 12 patients [83.3%] with grade 3-4), pre-diabetic (42 out of 159 patients [26.4%] with grade 1-2, and 77 out of 159 patients [48.4%] with grade 3-4), had BMI ≥30 at screening (13 out of 74 patients [17.6%] with grade 1-2, and 38 out of 74 patients [51.4%] with grade 3-4) or ≥75 years of age (6 out of 34 patients [17.6%] with grade 1-2, and 19 out of 34 patients [55.9%] with grade 3-4).

As hyperglycaemia may occur with a rapid onset after starting treatment, it is recommended to self-monitor frequently in the first 4 weeks and especially within the first 2 weeks of treatment, as clinically indicated. A specific schedule for fasting glucose monitoring is recommended in Table 6.

In the phase III clinical study, patients with a history of diabetes mellitus intensified use of antidiabetic medicinal products while on treatment with Piqray.

All patients should be instructed on lifestyle changes that may reduce hyperglycaemia (e.g. dietary restrictions and physical activity).

**Table 6  Schedule of fasting glucose monitoring**

<table>
<thead>
<tr>
<th>At screening, before initiating treatment with Piqray</th>
<th>Recommended schedule for monitoring of fasting glucose and HbA1c levels in all patients treated with Piqray</th>
<th>Recommended schedule of monitoring of fasting glucose and HbA1c levels in patients with diabetes, pre-diabetes, BMI ≥30 or age ≥75 years treated with Piqray</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test for fasting plasma glucose (FPG), HbA1c, and optimise the patient’s level of blood glucose (see Table 2).</td>
<td>Monitor fasting glucose at weeks 1, 2, 4, 6 and 8 after treatment start and monthly thereafter.</td>
<td>Monitor/self-monitor fasting glucose regularly, more frequently in the first 4 weeks and especially within the first 2 weeks of treatment, according to the instructions of a healthcare professional*. Then continue to monitor fasting glucose as frequently as needed to manage hyperglycaemia according to the instructions of a healthcare professional*. HbA1c should be monitored after 4 weeks of treatment and every 3 months thereafter.</td>
</tr>
<tr>
<td>Monitor fasting glucose at weeks 1, 2, 4, 6 and 8 after treatment start and monthly thereafter.</td>
<td>Monitor/self-monitor fasting glucose regularly, more frequently in the first 4 weeks and especially within the first 2 weeks of treatment, according to the instructions of a healthcare professional*.</td>
<td>Monitor/self-monitor fasting glucose regularly, as per local standard of care and at least until fasting glucose decreases to normal levels. During treatment with antidiabetic medication, continue monitoring fasting glucose at least once a week for 8 weeks, followed by once every 2 weeks, and monitor fasting glucose according to the instructions of a healthcare professional with expertise in the treatment of hyperglycaemia.</td>
</tr>
</tbody>
</table>

* All glucose monitoring should be performed at the physician’s discretion as clinically indicated.

Patients should be advised of the signs and symptoms of hyperglycaemia (e.g. excessive thirst, urinating more often than usual or greater amount of urine than usual, increased appetite with weight loss).

In the 190 patients with hyperglycaemia, 87.4% (166/190) were managed with antidiabetic medication, and 75.8% (144/190) reported use of metformin as single agent or in combination with other antidiabetic medication (e.g. insulin, dipeptidyl peptidase-4 (DPP-4) inhibitors, SGLT2 inhibitors and sulfonylureas).
Oral antidiabetic medication was used in 154 patients. Out of these 154 patients, 17 (11.0%) discontinued study treatment due to hyperglycaemia. Concomitant insulin medication was used in 54 patients; of these 13 (24.1%) discontinued study treatment due to hyperglycaemia.

Out of 162 patients with grade ≥2 hyperglycaemia, 155 had at least 1 grade improvement, median time to improvement from the first event was 8 days (95% CI: 8 to 10 days).

Of the patients with elevated FPG who continued fulvestrant treatment after discontinuing Piqray (n=58), 98.3% (n=57) had FPG levels that returned to baseline.

The safety of Piqray in patients with Type 1 and uncontrolled Type 2 diabetes has not been established as these patients were excluded from the phase III clinical study. Patients with a medical history of Type 2 diabetes were included. Patients with a history of diabetes mellitus may require intensified diabetic treatment and should be closely monitored.

Based on the severity of the hyperglycaemia, Piqray may require dose interruption, reduction or discontinuation as described in Table 2 (see section 4.2).

**Pneumonitis**

Pneumonitis, including serious cases of pneumonitis/acute interstitial lung disease, has been reported in Piqray-treated patients in clinical studies. Patients should be advised to report promptly any new or worsening respiratory symptoms. In patients who have new or worsening respiratory symptoms or are suspected to have developed pneumonitis, Piqray treatment should be interrupted immediately and the patient should be evaluated for pneumonitis. A diagnosis of non-infectious pneumonitis should be considered in patients presenting with non-specific respiratory signs and symptoms such as hypoxia, cough, dyspnoea, or interstitial infiltrates on radiological examination and in whom infectious, neoplastic and other causes have been excluded by means of appropriate investigations. Piqray should be permanently discontinued in all patients with confirmed pneumonitis.

**Diarrhoea or colitis**

Patients should be monitored for diarrhoea and other symptoms of colitis, such as abdominal pain and mucus or blood in stools.

Severe diarrhoea and clinical consequences, such as dehydration and acute kidney injury, have been reported during treatment with Piqray and resolved with appropriate intervention. 59.5% of patients (n=169) experienced diarrhoea during treatment with Piqray. Grade 3 diarrhoea occurred in 7% (n=20) of patients with no reported cases of grade 4. Among patients with grade 2 or 3 diarrhoea (n=76), the median time to onset was 50 days (range: 1 to 954 days).

Dose reductions of Piqray were required in 5.6% of patients and 2.8% of patients discontinued Piqray due to diarrhoea. In the 169 patients who experienced diarrhoea, antidiarrhoeal medications (e.g. loperamide) were required to manage symptoms in 64.5% (109/169).

Based on the severity of the diarrhoea or colitis, Piqray may require dose interruption, reduction or discontinuation as described in Table 4 (see section 4.2).

Patients should be advised to start antidiarrhoeal treatment, increase oral fluids and notify their physician if diarrhoea or other symptoms of colitis occur while taking Piqray. In case of colitis, additional treatment, such as steroids, may be considered as clinically indicated.
Osteonecrosis of the jaw

Caution should be exercised when Piqray and bisphosphonates or RANK-ligand inhibitors (e.g. denosumab) are used either simultaneously or sequentially. Piqray treatment should not be initiated in patients with ongoing osteonecrosis of the jaw from previous or concurrent treatment with bisphosphonates/denosumab. Patients should be advised to promptly report any new or worsening oral symptoms (such as dental mobility, pain or swelling, non-healing of mouth sores, or discharge) during treatment with Piqray.

In patients who develop osteonecrosis of the jaw, standard medical management should be initiated.

Symptomatic visceral disease

The efficacy and safety of this medicinal product have not been studied in patients with symptomatic visceral disease.

Sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially 'sodium-free'.

4.5 Interaction with other medicinal products and other forms of interaction

Medicinal products that may increase alpelisib plasma concentrations

BCRP inhibitors
Alpelisib is a substrate for BCRP in vitro. BCRP is involved in the hepatobiliary export and intestinal secretion of alpelisib, therefore inhibition of BCRP in the liver and in the intestine during elimination may lead to an increase in systemic exposure of alpelisib. Therefore, caution and monitoring for toxicity are advised during concomitant treatment with inhibitors of BCRP (e.g. eltrombopag, lapatinib, pantoprazole).

Medicinal products that may decrease alpelisib plasma concentrations

Acid-reducing agents
The co-administration of the H2 receptor antagonist ranitidine in combination with a single 300 mg oral dose of alpelisib slightly reduced the bioavailability of alpelisib and decreased overall exposure of alpelisib. In the presence of a low-fat low-calorie (LFLC) meal, AUCinf was decreased on average by 21% and Cmax by 36% with ranitidine. In the absence of food, the effect was more pronounced with a 30% decrease in AUCinf and a 51% decrease in Cmax with ranitidine compared to the fasted state without co-administration of ranitidine. Population pharmacokinetic analysis showed no significant effect of co-administration of acid-reducing agents, including proton pump inhibitors, H2 receptor antagonists and antacids, on the pharmacokinetics of alpelisib. Therefore, alpelisib can be co-administered with acid-reducing agents, provided alpelisib is taken immediately after food (see section 4.2).

CYP3A4 inducers
Once-daily administration of 600 mg rifampin (a strong CYP3A4 inducer) for 7 days followed by co-administration with a single 300 mg oral dose of alpelisib on day 8, decreased alpelisib Cmax by 38% and AUC by 57% in healthy adults (N=25). Co-administration of rifampin 600 mg once daily for 15 days with alpelisib 300 mg once daily starting from day 8 to day 15 decreased the steady-state alpelisib Cmax by 59% and AUC by 74%.
Co-administration with a strong CYP3A4 inducer decreases alpelisib AUC, which may reduce alpelisib efficacy. Co-administration of alpelisib with strong CYP3A4 inducers (e.g. apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John’s wort) should be avoided and selection of an alternative concomitant medicinal product, with no or minimal potential to induce CYP3A4, should be considered.

Medicinal products whose plasma concentrations may be altered by alpelisib

Based on the results of metabolic *in vitro* induction and inhibition studies, alpelisib may induce the metabolic clearance of co-administered medicinal products metabolised by CYP2B6, CYP2C9 and CYP3A and may inhibit the metabolic clearance of co-administered medicinal products metabolised by CYP2C8, CYP2C9, CYP2C19 and CYP3A4 (time-dependent inhibition) if sufficiently high concentrations are achieved *in vivo*.

**CYP3A4 substrates**

No dose adjustment is required when co-administering Piqray with CYP3A4 substrates (e.g. everolimus, midazolam).

In a drug-drug interaction study, co-administration of alpelisib with everolimus, a sensitive CYP3A4 substrate, confirmed that there are no clinically significant pharmacokinetic interactions (increase in AUC by 11.2%) between alpelisib and CYP3A4 substrates. No change in everolimus exposure was observed at alpelisib doses ranging from 250 to 300 mg.

Caution is recommended when Piqray is used in combination with CYP3A4 substrates that also possess an additional time-dependent inhibition and induction potential on CYP3A4 that affects their own metabolism (e.g. rifampicin, ribociclib, encorafenib).

**CYP2C9 substrates with narrow therapeutic index**

In the absence of clinical data on CYP2C9, caution is recommended. *In vitro* evaluations indicated that the pharmacological activity of CYP2C9 substrates with a narrow therapeutic index such as warfarin may be reduced by the CYP2C9 induction effects of alpelisib.

**CYP2B6 sensitive substrates with narrow therapeutic index**

Sensitive CYP2B6 substrates (e.g. bupropion) or CYP2B6 substrates with a narrow therapeutic window should be used with caution in combination with Piqray, as alpelisib may reduce the clinical activity of such medicinal products.

Substances that are substrates of transporters

*In vitro* evaluations indicated that alpelisib (and/or its metabolite BZG791) has a potential to inhibit the activities of OAT3 drug transporters and intestinal BCRP and P-gp. Piqray should be used with caution in combination with sensitive substrates of these transporters which exhibit a narrow therapeutic index because Piqray may increase the systemic exposure of these substrates.

**Hormonal contraceptives**

No clinical studies were conducted assessing the drug-drug-interaction potential between alpelisib and hormonal contraceptives.
4.6 Fertility, pregnancy and lactation

Piqray is indicated in men and postmenopausal women. It is not to be used in women who are, or may be, pregnant or breast-feeding (see section 4.1).

Women of childbearing potential/Contraception in males and females

Females of reproductive potential should be advised that animal studies and the mechanism of action have shown that alpelisib can be harmful to the developing foetus. Embryo-foetal development studies in rats and rabbits have demonstrated that oral administration of alpelisib during organogenesis induced embryotoxicity, foetotoxicity and teratogenicity (see section 5.3).

In case females of reproductive potential take Piqray, they should use effective contraception (e.g. double-barrier method) when taking Piqray and for at least 1 week after stopping treatment with Piqray.

Male patients with sexual partners who are pregnant, possibly pregnant or who could become pregnant should use condoms during sexual intercourse while taking Piqray and for at least 1 week after stopping treatment with Piqray.

Please refer to section 4.6 of the prescribing information for fulvestrant.

Pregnancy

Piqray is not indicated and is not to be used in women who are, or may be, pregnant (see section 4.1).

There are no data from the use of alpelisib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Piqray is not recommended during pregnancy and in women of childbearing potential not using contraception.

The pregnancy status of females of reproductive potential should be verified prior to starting treatment with Piqray.

Breast-feeding

It is not known if alpelisib is excreted in human or animal milk.

Because of the potential for serious adverse reactions in the breast-fed infant, it is recommended that women should not breast-feed during treatment and for at least 1 week after the last dose of Piqray.

Fertility

There are no clinical data available on the effects of alpelisib on fertility. Based on repeated dose toxicity and fertility studies in animals, alpelisib may impair fertility in males and females of reproductive potential (see section 5.3).

4.7 Effects on ability to drive and use machines

Piqray has minor influence on the ability to drive and use machines. Patients should be advised to be cautious when driving or using machines in case they experience fatigue or blurred vision during treatment (see section 4.8).
4.8 Undesirable effects

Summary of the safety profile

The safety profile is based on data from 284 patients in the Piqray plus fulvestrant arm of the double-blind, placebo-controlled phase III study.

The most common ADRs (reported at a frequency >20% in the combined mutant and non-mutant study population) were plasma glucose increased (79.2%), creatinine increased (67.6%), diarrhoea (59.5%), gamma-glutamyltransferase increased (53.2%), rash (51.8%), lymphocyte count decreased (55.3%), nausea (46.8%), alanine aminotransferase increased (44.0%), anaemia (44.0%), fatigue (43.3%), lipase increased (42.6%), decreased appetite (35.9%), stomatitis (30.3%), vomiting (28.5%), weight decreased (27.8%), hypocalcaemia (27.8%), plasma glucose decreased (26.8%), activated partial thromboplastin time (aPTT) prolonged (22.2%) and alopecia (20.4%).

The most common grade 3 or 4 ADRs (reported at a frequency ≥2%) were plasma glucose increased (39.1%), rash (19.4%), gamma-glutamyltransferase increased (12.0%), lymphocyte count decreased (9.2%), diarrhoea (7.0%), lipase increased (7.0%), hypokalaemia (6.3%), fatigue (5.6%), weight decreased (5.3%), anaemia (4.9%), hypertension (4.6%), alanine aminotransferase increased (4.2%), nausea (2.8%), creatinine increased (2.8%), stomatitis (2.5%), hypocalcaemia (2.1%) and mucosal inflammation (2.1%).

The most common ADRs leading to treatment discontinuation were hyperglycaemia (6.3%), rash (4.2%), diarrhoea (2.8%) and fatigue (2.5%).

Tabulated list of adverse reactions

ADRs from the phase III clinical study and post-marketing experience (Table 7) are listed by MedDRA system organ class. Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, ADRs are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Table 7  **ADRs observed in phase III clinical study and during post-marketing experience**

<table>
<thead>
<tr>
<th>Adverse drug reaction</th>
<th>Any grade (%)</th>
<th>Grade 3 or 4 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infections and infestations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary tract infection¹</td>
<td>Very common</td>
<td>29 (10.2)</td>
</tr>
<tr>
<td><strong>Blood and lymphatic system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaemia</td>
<td>Very common</td>
<td>125 (44.0)</td>
</tr>
<tr>
<td>Lymphocyte count decreased</td>
<td>Very common</td>
<td>157 (55.3)</td>
</tr>
<tr>
<td>Platelet count decreased</td>
<td>Very common</td>
<td>43 (15.1)</td>
</tr>
<tr>
<td><strong>Immune system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypersensitivity²</td>
<td>Common</td>
<td>11 (3.9)</td>
</tr>
<tr>
<td><strong>Metabolism and nutrition disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose plasma increased</td>
<td>Very common</td>
<td>225 (79.2)</td>
</tr>
<tr>
<td>Glucose plasma decreased</td>
<td>Very common</td>
<td>76 (26.8)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>Very common</td>
<td>102 (35.9)</td>
</tr>
<tr>
<td>Hypokalaemia</td>
<td>Very common</td>
<td>42 (14.8)</td>
</tr>
<tr>
<td>Hypocalcaemia</td>
<td>Very common</td>
<td>79 (27.8)</td>
</tr>
<tr>
<td>Magnesium decreased</td>
<td>Very common</td>
<td>34 (12.0)</td>
</tr>
<tr>
<td>Dehydration</td>
<td>Common</td>
<td>10 (3.5)</td>
</tr>
<tr>
<td>KETOACIDOSIS³</td>
<td>Uncommon</td>
<td>2 (0.7)</td>
</tr>
<tr>
<td>Hyperglycaemic hyperosmolar nonketotic syndrome (HHNKS)⁴</td>
<td>Not known</td>
<td>Not known</td>
</tr>
<tr>
<td><strong>Psychiatric disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insomnia</td>
<td>Common</td>
<td>22 (7.7)</td>
</tr>
<tr>
<td><strong>Nervous system disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>Very common</td>
<td>55 (19.4)</td>
</tr>
<tr>
<td>Dysgeusia⁵</td>
<td>Very common</td>
<td>44 (15.5)</td>
</tr>
<tr>
<td><strong>Eye disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vision blurred</td>
<td>Common</td>
<td>15 (5.3)</td>
</tr>
<tr>
<td>Dry eye</td>
<td>Common</td>
<td>10 (3.5)</td>
</tr>
<tr>
<td><strong>Vascular disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>Common</td>
<td>27 (9.5)</td>
</tr>
<tr>
<td>Lymphoedema</td>
<td>Common</td>
<td>16 (5.6)</td>
</tr>
<tr>
<td><strong>Respiratory, thoracic and mediastinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonitis⁶</td>
<td>Common</td>
<td>5 (1.8)</td>
</tr>
<tr>
<td><strong>Gastrointestinal disorders</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>Very common</td>
<td>169 (59.5)</td>
</tr>
<tr>
<td>Nausea</td>
<td>Very common</td>
<td>133 (46.8)</td>
</tr>
<tr>
<td>Stomatitis⁷</td>
<td>Very common</td>
<td>86 (30.3)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>Very common</td>
<td>81 (28.5)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>Very common</td>
<td>50 (17.6)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>Very common</td>
<td>33 (11.6)</td>
</tr>
<tr>
<td>Toothache</td>
<td>Common</td>
<td>13 (4.6)</td>
</tr>
<tr>
<td>Gingivitis</td>
<td>Common</td>
<td>11 (3.9)</td>
</tr>
<tr>
<td>Gingival pain</td>
<td>Common</td>
<td>9 (3.2)</td>
</tr>
<tr>
<td>Chelitis</td>
<td>Common</td>
<td>8 (2.8)</td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>Uncommon</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Colitis⁸</td>
<td>Not known</td>
<td>Not known</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Very common</td>
<td>147 (51.8)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-------------</td>
<td>------------</td>
</tr>
<tr>
<td>Rash</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alopecia</td>
<td>Very common</td>
<td>58 (20.4)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>Very common</td>
<td>53 (18.7)</td>
</tr>
<tr>
<td>Dry skin#</td>
<td>Very common</td>
<td>53 (18.7)</td>
</tr>
<tr>
<td>Erythema#</td>
<td>Common</td>
<td>18 (6.3)</td>
</tr>
<tr>
<td>Dermatitis</td>
<td>Common</td>
<td>10 (3.5)</td>
</tr>
<tr>
<td>Palmar-plantar erythrodysaesthesia syndrome</td>
<td>Common</td>
<td>5 (1.8)</td>
</tr>
<tr>
<td>Erythema multiforme</td>
<td>Common</td>
<td>3 (1.1)</td>
</tr>
<tr>
<td>Stevens-Johnson syndrome</td>
<td>Uncommon</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Drug reaction with eosinophilia and systemic symptoms (DRESS)#</td>
<td>Not known</td>
<td>Not known</td>
</tr>
<tr>
<td>Angioedema#</td>
<td>Not known</td>
<td>Not known</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Musculoskeletal and connective tissue disorders</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle spasms</td>
<td>Common</td>
</tr>
<tr>
<td>Myalgia</td>
<td>Common</td>
</tr>
<tr>
<td>Osteonecrosis of jaw</td>
<td>Common</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Renal and urinary disorders</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute kidney injury</td>
<td>Common</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>General disorders and administration site conditions</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue¹¹</td>
<td>Very common</td>
</tr>
<tr>
<td>Mucosal inflammation</td>
<td>Very common</td>
</tr>
<tr>
<td>Oedema peripheral</td>
<td>Very common</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>Very common</td>
</tr>
<tr>
<td>Mucosal dryness¹²</td>
<td>Very common</td>
</tr>
<tr>
<td>Oedema¹³</td>
<td>Common</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Investigations</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight decreased</td>
<td>Very common</td>
</tr>
<tr>
<td>Blood creatinine increased</td>
<td>Very common</td>
</tr>
<tr>
<td>Gamma-glutamyltransferase increased</td>
<td>Very common</td>
</tr>
<tr>
<td>Alanine aminotransferase increased</td>
<td>Very common</td>
</tr>
<tr>
<td>Lipase increased</td>
<td>Very common</td>
</tr>
<tr>
<td>Activated partial thromboplastin time (aPTT) prolonged</td>
<td>Very common</td>
</tr>
<tr>
<td>Albumin decreased</td>
<td>Very common</td>
</tr>
<tr>
<td>Glycosylated haemoglobin increased</td>
<td>Common</td>
</tr>
</tbody>
</table>

Table: Skin and subcutaneous tissue disorders

<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rash</td>
<td>Very common</td>
<td>147 (51.8)</td>
</tr>
<tr>
<td>Alopecia</td>
<td>Very common</td>
<td>58 (20.4)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>Very common</td>
<td>53 (18.7)</td>
</tr>
<tr>
<td>Dry skin</td>
<td>Very common</td>
<td>53 (18.7)</td>
</tr>
<tr>
<td>Erythema</td>
<td>Common</td>
<td>18 (6.3)</td>
</tr>
<tr>
<td>Dermatitis</td>
<td>Common</td>
<td>10 (3.5)</td>
</tr>
<tr>
<td>Palmar-plantar erythrodysaesthesia syndrome</td>
<td>Common</td>
<td>5 (1.8)</td>
</tr>
<tr>
<td>Erythema multiforme</td>
<td>Common</td>
<td>3 (1.1)</td>
</tr>
<tr>
<td>Stevens-Johnson syndrome</td>
<td>Uncommon</td>
<td>1 (0.4)</td>
</tr>
<tr>
<td>Drug reaction with eosinophilia and systemic symptoms (DRESS)#</td>
<td>Not known</td>
<td>Not known</td>
</tr>
<tr>
<td>Angioedema</td>
<td>Not known</td>
<td>Not known</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle spasms</td>
<td>Common</td>
<td>22 (7.7)</td>
</tr>
<tr>
<td>Myalgia</td>
<td>Common</td>
<td>19 (6.7)</td>
</tr>
<tr>
<td>Osteonecrosis of jaw</td>
<td>Common</td>
<td>16 (5.6)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute kidney injury</td>
<td>Common</td>
<td>16 (5.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5 (1.8)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue¹¹</td>
<td>Very common</td>
<td>123 (43.3)</td>
</tr>
<tr>
<td>Mucosal inflammation</td>
<td>Very common</td>
<td>56 (19.7)</td>
</tr>
<tr>
<td>Oedema peripheral</td>
<td>Very common</td>
<td>47 (16.5)</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>Very common</td>
<td>45 (15.8)</td>
</tr>
<tr>
<td>Mucosal dryness¹²</td>
<td>Very common</td>
<td>36 (12.7)</td>
</tr>
<tr>
<td>Oedema¹³</td>
<td>Common</td>
<td>18 (6.3)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight decreased</td>
<td>Very common</td>
<td>79 (27.8)</td>
</tr>
<tr>
<td>Blood creatinine increased</td>
<td>Very common</td>
<td>192 (67.6)</td>
</tr>
<tr>
<td>Gamma-glutamyltransferase increased</td>
<td>Very common</td>
<td>151 (53.2)</td>
</tr>
<tr>
<td>Alanine aminotransferase increased</td>
<td>Very common</td>
<td>125 (44.0)</td>
</tr>
<tr>
<td>Lipase increased</td>
<td>Very common</td>
<td>121 (42.6)</td>
</tr>
<tr>
<td>Activated partial thromboplastin time (aPTT) prolonged</td>
<td>Very common</td>
<td>63 (22.2)</td>
</tr>
<tr>
<td>Albumin decreased</td>
<td>Very common</td>
<td>41 (14.4)</td>
</tr>
<tr>
<td>Glycosylated haemoglobin increased</td>
<td>Common</td>
<td>8 (2.8)</td>
</tr>
</tbody>
</table>

Table: Investigators

<table>
<thead>
<tr>
<th>Condition</th>
<th>Frequency</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight decreased</td>
<td>Very common</td>
<td>79 (27.8)</td>
</tr>
<tr>
<td>Blood creatinine increased</td>
<td>Very common</td>
<td>192 (67.6)</td>
</tr>
<tr>
<td>Gamma-glutamyltransferase increased</td>
<td>Very common</td>
<td>151 (53.2)</td>
</tr>
<tr>
<td>Alanine aminotransferase increased</td>
<td>Very common</td>
<td>125 (44.0)</td>
</tr>
<tr>
<td>Lipase increased</td>
<td>Very common</td>
<td>121 (42.6)</td>
</tr>
<tr>
<td>Activated partial thromboplastin time (aPTT) prolonged</td>
<td>Very common</td>
<td>63 (22.2)</td>
</tr>
<tr>
<td>Albumin decreased</td>
<td>Very common</td>
<td>41 (14.4)</td>
</tr>
<tr>
<td>Glycosylated haemoglobin increased</td>
<td>Common</td>
<td>8 (2.8)</td>
</tr>
</tbody>
</table>

* No grade 4 ADRs were observed

# Adverse reactions reported during post-marketing experience. These are derived from spontaneous reports for which it is not always possible to reliably establish frequency or a causal relationship to exposure to the medicinal product.

1. Urinary tract infection: also includes a single case of urosepsis
2. Hypersensitivity: also includes allergic dermatitis
3. Ketoacidosis: also includes diabetic ketoacidosis (see section 4.4)
4. Dysgeusia: also includes ageusia, hypogeusia
5. Pneumonitis: also includes interstitial lung disease
6. Stomatitis: also includes aphthous ulcer and mouth ulceration
7. Rash: also includes rash maculopapular, rash macular, rash generalised, rash papular, rash pruritic
8. Dry skin: also includes skin fissures, xerosis, xeroderma
9. Erythema: also includes erythema generalised
10. Dermatitis: also includes dermatitis aciform
11. Fatigue: also includes asthenia
12. Mucosal dryness: also includes dry mouth, vulvovaginal dryness
13. Oedema: also includes face swelling, face oedema, eyelid oedema
Description of selected ADRs

Hyperglycaemia

Hyperglycaemia (FPG >160 mg/dl) was reported in 190 (66.9%) patients; grade 2 (FPG 160-250 mg/dl), 3 (FPG >250-500 mg/dl) and 4 (FPG >500 mg/dl) events were reported in 16.2%, 33.8% and 4.6% of patients, respectively.

Based on baseline FPG and HbA1c values, 56% of patients were considered pre-diabetic (FPG >100-126 mg/dl [5.6 to 6.9 mmol/l] and/or HbA1c 5.7-6.4%) and 4.2% of patients were considered diabetic (FPG ≥126 mg/dl [≥7.0 mmol/l] and/or HbA1c ≥6.5%). 74.8% of patients who were pre-diabetic at baseline experienced hyperglycaemia (any grade) when treated with alpelisib. Among all patients with hyperglycaemia of grade ≥2 (FPG ≥160 mg/dl), the median time to first occurrence was 15 days (range: 5 days to 900 days) (based on laboratory findings). The median duration of grade ≥2 hyperglycaemia was 10 days (95% CI: 8 to 13 days). In patients with grade ≥2 hyperglycaemia, median time to improvement (at least one grade from the first event) was 8 days (95% CI: 8 to 10 days). In all patients who continued on fulvestrant after discontinuing Piqray, FPG levels returned to baseline (normal).

Hyperglycaemia was managed with antidiabetic medicinal products, see section 4.4.

Rash

Rash events (including rash maculopapular, macular, generalised, papular and pruritic, dermatitis and dermatitis acneiform) were reported in 153 (53.9%) patients. Rash was predominantly mild or moderate (grade 1 or 2) and responsive to therapy, and in some cases rash was accompanied by pruritus and dry skin. Grade 2 and 3 events were reported in 13.7% and 20.1% of patients, respectively, with a median time to first onset of 12 days (range: 2 days to 220 days).

Among patients who received prophylactic antirash treatment including antihistamines, rash was reported less frequently than in the overall population; 26.1% vs 53.9% for all grades, 11.4% vs 20.1% for grade 3, and 3.4% vs 4.2% for rash leading to the permanent discontinuation of Piqray. Accordingly, antihistamines may be initiated prophylactically, at the time of initiation of treatment with Piqray.

Gastrointestinal toxicity (nausea, diarrhoea, vomiting)

Diarrhoea, nausea and vomiting were reported in 59.5%, 46.8% and 28.5% of the patients, respectively (see Table 7).

Grade 2 and 3 diarrhoea events were reported in 19.7% and 7.0% of patients, respectively, with a median time to onset of grade ≥2 diarrhoea of 50 days (range: 1 day to 954 days).

Severe diarrhoea and clinical consequences, such as dehydration and acute kidney injury, have been reported during treatment with Piqray and resolved with appropriate intervention (see Table 4). Antiemetics (e.g. ondansetron) and antidiarrhoeal medicinal products (e.g. loperamide) were used in 28/153 (17.6%) and 109/169 (64.5%) patients, respectively, to manage symptoms.

Osteonecrosis of the jaw (ONJ)

ONJ was reported in 5.6% patients (16/284) in the Piqray plus fulvestrant arm. Fifteen patients experiencing ONJ were exposed to concomitant bisphosphonates (e.g. zoledronic acid) or RANK-ligand inhibitors (e.g. denosumab). Therefore, in patients receiving Piqray and bisphosphonates or RANK-ligand inhibitors, an increased risk of development of ONJ cannot be excluded.

Elderly

In patients ≥65 years of age treated with alpelisib plus fulvestrant, there was a higher incidence of grade 3-4 hyperglycaemia (45.3%) compared to patients <65 years of age (33.5%), while in patients <75 years of age, grade 3-4 hyperglycaemia was 36% compared to 55.9% in patients ≥75 years of age.
Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

Symptoms

The adverse reactions associated with overdose have been consistent with the safety profile of Piqray and included hyperglycaemia, nausea, asthenia and rash.

Management

General symptomatic and supportive measures should be initiated in all cases of overdose where necessary. There is no known antidote for Piqray.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, other antineoplastic agents, ATC code: L01EM03

Mechanism of action

Alpelisib is an \( \alpha \)-specific class I phosphatidylinositol3kinase (PI3K\( \alpha \)) inhibitor. Gain-of-function mutations in the gene encoding the catalytic \( \alpha \)-subunit of PI3K (PIK3CA) lead to activation of PI3K\( \alpha \) and AKT-signalling, cellular transformation and the generation of tumours in \textit{in vitro} and \textit{in vivo} models.

In breast cancer cell lines, alpelisib inhibited the phosphorylation of PI3K downstream targets including AKT, and showed activity in cell lines harbouring a PIK3CA mutation.

\textit{In vivo}, alpelisib inhibited the PI3K/AKT signalling pathway and reduced tumour growth in xenograft models, including models of breast cancer.

PI3K inhibition by alpelisib treatment has been shown to induce an increase in oestrogen receptor (ER) transcription in breast cancer cells. The combination of alpelisib and fulvestrant demonstrated increased anti-tumour activity compared to either treatment alone in xenograft models derived from ER-positive, PIK3CA mutated breast cancer cell lines.

The PI3K/AKT signalling pathway is responsible for glucose homeostasis, and hyperglycaemia is an expected on-target adverse reaction of PI3K inhibition.
Clinical efficacy and safety

Piqray was evaluated in a pivotal phase III, randomised, double-blind, placebo-controlled study of alpelisib in combination with fulvestrant in postmenopausal women, and men, with HR+, HER2- advanced (locoregionally recurrent or metastatic) breast cancer whose disease had progressed or recurred on or after an aromatase-inhibitor-based treatment (with or without CDK4/6 combination).

A total of 572 patients were enrolled into two cohorts, one cohort with PIK3CA mutation and one cohort without PIK3CA mutation breast cancer. Patients were randomised to receive either alpelisib 300 mg plus fulvestrant or placebo plus fulvestrant in a 1:1 ratio. Randomisation was stratified by presence of lung and/or liver metastasis and previous treatment with CDK4/6 inhibitor(s).

In the cohort with PIK3CA mutation, 169 patients with one or more PIK3CA mutations (C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R or H1047Y) were randomised to receive alpelisib in combination with fulvestrant and 172 patients were randomised to receive placebo in combination with fulvestrant. In this cohort 170 (49.9%) patients had liver/lung metastases and 20 (5.9%) patients had received prior CDK4/6 inhibitor treatment.

Patients had a median age of 63 years (range: 25 to 92 years). 44.9% patients were 65 years of age or older and ≤85 years. The patients included were White (66.3%), Asian (21.7%) and Black or African American (1.2%). The study population included one male subject enrolled in the PIK3CA mutant cohort and treated with alpelisib and fulvestrant. 66.0% and 33.4% of subjects had an ECOG performance status of 0 and 1, respectively.

97.7% of patients had received prior endocrine therapy. In 67.7% of subjects, the last therapy prior to study enrollment was endocrine therapy. Letrozole and anastrozole were the most commonly used endocrine therapies. The setting of last endocrine therapy prior to study enrollment was therapeutic in 47.8% of subjects and adjuvant therapy in 51.9% of subjects. Overall, 85.6% of the patients were considered to have endocrine-resistant disease; primary endocrine resistance (de novo resistance) was observed in 13.2% and secondary endocrine resistance (relapse/progression following an initial response) in 72.4% of patients.

Demographics and baseline disease characteristics, ECOG performance status, tumour burden and prior antineoplastic therapy were well balanced between the study arms.

During the randomised treatment phase, alpelisib 300 mg or placebo was administered orally once daily on a continuous basis. Fulvestrant 500 mg was administered intramuscularly on cycle 1 days 1 and 15 and then at day 1 of a 28-day cycle during treatment phase (administration ±3 days).

Patients were not allowed to cross over from placebo to alpelisib during the study or after disease progression.

The primary endpoint for the study was progression-free survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST v1.1), based on the investigator assessment in patients with a PIK3CA mutation. The key secondary endpoint was overall survival (OS) for patients with a PIK3CA mutation.

Other secondary endpoints included PFS for patients without a PIK3CA mutation, OS for patients without a PIK3CA mutation.
Primary efficacy analysis

The study met its primary objective at the final PFS analysis (cut-off date 12-Jun-2018), demonstrating a statistically significant improvement in PFS per investigator assessment in the PIK3CA mutant cohort for patients receiving alpelisib plus fulvestrant, compared to patients receiving placebo plus fulvestrant with an estimated 35% risk reduction of disease progression or death in favour of treatment with alpelisib plus fulvestrant (see Table 8).

Table 8  Study C2301 primary efficacy analysis - Summary of efficacy results based on RECIST (FAS, cohort with PIK3CA mutation). Data cut-off date: 12-Jun-2018

<table>
<thead>
<tr>
<th></th>
<th>Piqray + fulvestrant (n=169)</th>
<th>Placebo + fulvestrant (n=172)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median progression free survival (PFS) (months, 95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investigator radiological assessment</td>
<td>11.0 (7.5 to 14.5)</td>
<td>5.7 (3.7 to 7.4)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.65 (0.50 to 0.85)</td>
<td></td>
</tr>
<tr>
<td>p-value*</td>
<td>0.00065</td>
<td></td>
</tr>
<tr>
<td>Blinded independent review committee assessment**</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PIK3CA mutant cohort (N=173)</td>
<td>11.1 (7.3 to 16.8)</td>
<td>3.7 (2.1 to 5.6)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.48 (0.32 to 0.71)</td>
<td></td>
</tr>
<tr>
<td>p-value</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

CI = confidence interval; N = number of patients; N/A = is not applicable
* p-value is obtained from the one-sided stratified log-rank test.
** Per RECIST 1.1
Based on 50% sample-based audit approach.

In the cohort with PIK3CA mutation, PFS subgroup analyses per investigator assessment by randomisation stratification factors showed a generally consistent treatment effect in favour of the alpelisib arm, irrespective of presence or absence of lung/liver metastases.

Among 20 patients with prior CDK4/6 inhibitor use the hazard ratio (HR) for PFS was 0.48 (95% CI: 0.17, 1.36); median PFS was 1.8 months (95% CI: 1.7, 3.6) in the placebo plus fulvestrant arm and 5.5 months (95% CI: 1.6, 16.8) in the alpelisib plus fulvestrant arm.

Using a data cut-off date of 12-Jun-2018, PFS results for the subgroup of endocrine resistant patients (HR=0.64; 95% CI: 0.49, 0.85, n=292) and endocrine sensitive patients (HR=0.87; 95% CI: 0.35, 2.17, n=39) were in favour of the alpelisib plus fulvestrant arm. The number of endocrine sensitive patients with a PIK3CA mutation was limited (n=39) and the results should be interpreted with caution.

Using a data cut-off date of 12-Jun-2018, the overall response rate in patients with measurable disease at baseline was 35.7% (95% CI: 27.4, 44.7) in the alpelisib plus fulvestrant arm and 16.2% (95% CI: 10.4, 23.5) in the placebo plus fulvestrant arm.

At the time when the final OS analysis was conducted (data cut-off date of 23-Apr-2020) a descriptive follow-up efficacy analysis for PFS data was performed. With a median duration from randomisation to data cut-off of approximately 42 months, the reported PFS results were consistent with those from the primary PFS analysis. There was an estimated 36% risk reduction of progression or death in favour of treatment with alpelisib plus fulvestrant (HR=0.64; 95% CI: 0.50, 0.81) (Figure 1).
Figure 1  Study C2301 - Kaplan-Meier plot of PFS per investigator assessment (FAS, PIK3CA mutant cohort): descriptive update with data cut-off date of 23-Apr-2020

![Kaplan-Meier plot with placebo and Alpelisib + Fulvestrant](image)

- **Censoring times**
- **Alpelisib + Fulv. (n/N = 124/169)**
- **Placebo + Fulv. (n/N = 149/172)**

Hazard ratio = 0.64
95% CI [0.50; 0.81]
Kaplan-Meier medians (months)
- **Alpelisib + fulv.: 11.0**
- **Placebo + fulv.: 5.7**

### Number of subjects still at risk

<table>
<thead>
<tr>
<th>Time (months)</th>
<th>0</th>
<th>4</th>
<th>8</th>
<th>12</th>
<th>16</th>
<th>20</th>
<th>24</th>
<th>28</th>
<th>32</th>
<th>36</th>
<th>40</th>
<th>44</th>
<th>48</th>
<th>52</th>
<th>56</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alpelisib + fulv.</strong></td>
<td>169</td>
<td>123</td>
<td>85</td>
<td>66</td>
<td>54</td>
<td>44</td>
<td>37</td>
<td>29</td>
<td>24</td>
<td>18</td>
<td>12</td>
<td>6</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td><strong>Placebo + fulv.</strong></td>
<td>172</td>
<td>89</td>
<td>67</td>
<td>51</td>
<td>40</td>
<td>33</td>
<td>22</td>
<td>13</td>
<td>10</td>
<td>7</td>
<td>4</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

Event-free probability (%)
**Final overall survival analysis**

At the final OS analysis, the study did not meet its key secondary objective. As of the data cut-off date of 23-Apr-2020, a total of 87 (51.5%) deaths were reported in the alpelisib plus fulvestrant arm and 94 (54.7%) in the placebo plus fulvestrant arm. The HR was 0.86 (95% CI: 0.64, 1.15; p=0.15, one-sided) and the pre-specified O’Brien-Fleming efficacy boundary of p ≤0.0161 was not crossed. Median OS was 39.3 months (95% CI: 34.1, 44.9) in the alpelisib plus fulvestrant arm and 31.4 months (95% CI: 26.8, 41.3) in the placebo plus fulvestrant arm (Figure 2).

**Figure 2**  Study C2301 key secondary analysis – Kaplan-Meier plot of OS (FAS, PIK3CA mutant cohort) with cut-off date of 23-Apr-2020

In patients with prior CDK4/6i treatment (n=20), the median OS in the alpelisib plus fulvestrant arm was 29.8 months (95% CI: 6.7, 38.2) compared to 12.9 months (95% CI: 2.5, 34.6) in the placebo plus fulvestrant arm (HR=0.67; 95% CI: 0.21, 2.18).

**Cohort without PIK3CA mutation**

No PFS benefit was observed in patients whose tumours did not have a PIK3CA tissue mutation.

**Prior use of fulvestrant in study CBYL719X2102**

Patients with prior fulvestrant use were not included in the pivotal study. In the phase I study CBYL719X2101, 39 subjects reported prior fulvestrant use. The best overall responses to treatment with alpelisib plus fulvestrant for the 21 subjects with PIK3CA mutations and measurable disease at baseline were partial response in 7 subjects, stable disease in 11 subjects, and progressive disease in 2 subjects. Hence, the evidence of efficacy of this treatment in patients previously treated with fulvestrant is not established due to the limited data at this time (see section 4.4).

**Paediatric population**

The European Medicines Agency has waived the obligation to submit the results of studies with Pizray in all subsets of the paediatric population in breast cancer (see section 4.2 for information on paediatric use).
5.2 Pharmacokinetic properties

The pharmacokinetics of alpelisib were investigated in patients under an oral dosing regimen ranging from 30 to 450 mg daily. Healthy subjects received single oral doses ranging from 300 to 400 mg. The pharmacokinetics were comparable in both oncology patients and healthy subjects.

Absorption

Following oral administration of alpelisib, median time to reach peak plasma concentration (\(T_{\text{max}}\)) ranged between 2.0 to 4.0 hours, independent of dose, time or regimen. Based on absorption modelling bioavailability was estimated to be very high (>99%) under fed conditions but lower under fasted conditions (~68.7% at a 300 mg dose). Steady-state plasma levels of alpelisib after daily dosing can be expected to be reached on day 3 following onset of therapy in most patients.

Food effect

Alpelisib absorption is affected by food. In healthy volunteers after a single 300 mg oral dose of alpelisib, compared to the fasted state, a high-fat high-calorie (HFHC) meal (985 calories with 58.1 g of fat) increased AUC\(_{\text{inf}}\) by 73% and \(C_{\text{max}}\) by 84%, and a LFLC meal (334 calories with 8.7 g of fat) increased AUC\(_{\text{inf}}\) by 77% and \(C_{\text{max}}\) by 145%. No significant difference was found for AUC\(_{\text{inf}}\) between LFLC and HFHC with a geometric mean ratio of 0.978 (CI: 0.876, 1.09), showing that neither fat content nor overall caloric intake has a considerable impact on absorption. The increase in gastrointestinal solubility by bile, secreted in response to food intake, is the potential cause of the food effect. Hence, PIqray should be taken immediately after food at approximately same time each day.

Distribution

Alpelisib moderately binds to protein with a free fraction of 10.8% regardless of concentration. Alpelisib was equally distributed between red blood cells and plasma with a mean in vivo blood-to-plasma ratio of 1.03. As alpelisib is a substrate of human efflux transporters, penetration of the blood-brain barrier is not expected to occur in humans. The volume of distribution of alpelisib at steady state (\(V_{\text{ss/F}}\)) is estimated at 114 litres (intersubject CV% 46%).

Biotransformation

In vitro studies demonstrated that formation of the hydrolysis metabolite BZG791 by chemical and enzymatic amide hydrolysis was a major metabolic pathway, followed by CYP3A4-mediated hydroxylation. Alpelisib hydrolysis occurs systemically by both chemical decomposition and enzymatic hydrolysis via ubiquitously expressed, high-capacity enzymes (esterases, amidases, choline esterase) not limited to the liver. CYP3A4-mediated metabolites and glucuronides amounted to ~15% of the dose; BZG791 accounted for ~40-45% of the dose. The rest of the dose, which was found as unchanged alpelisib in urine and faeces, was either excreted as alpelisib or not absorbed.

Elimination

Alpelisib exhibits low clearance with 9.2 l/h (CV% 21%) based on population pharmacokinetic analysis under fed conditions. The population-derived half-life, independent of dose and time, was 8 to 9 hours at steady state with 300 mg once daily.

In a human mass-balance study, after oral administration, alpelisib and its metabolites were primarily found in the faeces (81.0%) as alpelisib, or metabolised as BZG791. Excretion in the urine is minor (13.5%), with unchanged alpelisib (2%). Following a single oral dose of [14C]-alpelisib, 94.5% of the total administered radioactive dose was recovered within 8 days.
Linearity/non-linearity

The pharmacokinetics were found to be linear with respect to dose and time under fed conditions between 30 and 450 mg. After multiple doses, alpelisib exposure (AUC) at steady state is only slightly higher than that of a single dose, with an average accumulation of 1.3 to 1.5 with a daily dosing regimen.

Metabolic interaction

CYP3A4 substrates
In a drug-drug interaction study with the sensitive CYP3A4 substrate everolimus, AUC increased by 11.2%. No clinically meaningful change is expected as a result of drug interaction with CYP3A4 substrates.

CYP3A4 inducers
In a drug-drug interaction study co-administration of alpelisib and rifampin, a strong CYP3A4 inducer, confirmed that there is a clinically significant pharmacokinetic interaction between alpelisib and strong CYP3A4 inducers (see section 4.5).

Transporter-based interaction

Based on in vitro data, inhibition of the renal organic anion transporter OAT3 by alpelisib (and/or its metabolite BZG791) cannot be discarded in patients at the therapeutic dose.

Alpelisib showed only weak in vitro inhibition towards the ubiquitously expressed efflux transporters (P-gp, BCRP, MRP2, BSEP), solute carrier transporters at the liver inlet (OATP1B1, OATP1B3, OCT1) and solute carrier transporters in the kidney (OAT1, OCT2, MATE1, MATE2K). As unbound systemic steady-state concentrations (or concentrations at the liver inlet) at both the therapeutic dose and maximum tolerated dose are significantly lower than the experimentally determined unbound inhibition constants or IC50, the inhibition will not translate into clinical significance. Due to high alpelisib concentrations in the intestinal lumen, an effect on intestinal P-gp and BCRP cannot be fully excluded.

Special populations

Effect of age, weight and gender
The population pharmacokinetic analysis showed that there are no clinically relevant effects of age, body weight, or gender on the systemic exposure of alpelisib that would require Piqray dose adjustment.

Paediatric patients (below 18 years)
The pharmacokinetics of Piqray in children aged 0-18 years have not been established. No data are available.

Elderly (age 65 years or above)
Of 284 patients who received Piqray in the phase III study (in the alpelisib plus fulvestrant arm), 117 patients were ≥65 years of age and 34 patients were between 75 and 87 years of age. No overall differences in exposure of Piqray were observed between these patients and younger patients (see section 4.2).

Race/Ethnicity
Population pharmacokinetic analyses and pharmacokinetic analyses from a phase I study in Japanese cancer patients showed that there are no clinically relevant effects of ethnicity on the systemic exposure of Piqray.

Non-compartmental pharmacokinetic parameters after single and multiple daily doses of Piqray for Japanese patients were very similar to those reported in the Caucasian population.
Renal impairment
Based on a population pharmacokinetic analysis that included 117 patients with normal renal function (eGFR ≥ 90 ml/min/1.73 m²) / (CLcr ≥ 90 ml/min), 108 patients with mild renal impairment (eGFR 60 to < 90 ml/min/1.73 m²) / (CLcr 60 to < 90 ml/min), and 45 patients with moderate renal impairment (eGFR 30 to < 60 ml/min/1.73 m²), mild and moderate renal impairment had no effect on the exposure of alpelisib (see section 4.2).

Hepatic impairment
Based on a pharmacokinetic study in patients with hepatic impairment, moderate and severe hepatic impairment had negligible effect on the exposure of alpelisib (see section 4.2). The mean exposure for alpelisib was increased 1.26-fold in patients with severe (GMR: 1.00 for Cmax; 1.26 for AUClast/AUCinf) hepatic impairment.

Based on a population pharmacokinetic analysis that included 230 patients with normal hepatic function, 41 patients with mild hepatic impairment and no patients with moderate hepatic impairment, further supporting the findings from the dedicated hepatic impairment study, mild and moderate hepatic impairment had no effect on the exposure of alpelisib (see section 4.2).

5.3 Preclinical safety data
Safety pharmacology and repeated dose toxicity
The majority of the observed alpelisib effects were related to the pharmacological activity of alpelisib as a p110α-specific inhibitor of the PI3K pathway, such as the influence on the glucose homeostasis resulting in hyperglycaemia and the risk of increased blood pressure. The bone marrow and lymphoid tissue, pancreas and some reproductive organs of both genders were the main target organs for adverse effects. Effects on bone marrow and lymphoid tissue were generally reversible on cessation of treatment. Effects on the pancreas and reproductive organs did not fully reverse but showed a tendency towards reversion. In exploratory rat studies evidence of inflammatory changes of the skin was found.

Cardiovascular safety pharmacology
In vitro inhibition of hERG channels (IC50 of 9.4 μM) was shown at concentrations ~13-fold higher than the exposure in humans, at the recommended dose of 300 mg/day. No relevant electrophysiological effect was seen in dogs.

Carcinogenicity and mutagenicity
No carcinogenicity studies have been conducted.

Results of standard genotoxicity in vitro studies with alpelisib were negative. Alpelisib was not genotoxic in a repeated-dose rat toxicity study where micronucleus analysis was integrated, up to exposure levels approximately twice the estimated exposure (AUC) in humans at the recommended dose of 300 mg.

Reproductive toxicity
Embryo-foetal development studies in rats and rabbits have demonstrated that oral administration of alpelisib during organogenesis induced embryotoxicity, foetotoxicity and teratogenicity. In rats and rabbits, following prenatal exposure to alpelisib, increased incidences of pre- and post-implantation losses, reduced foetal weights and increased incidences of foetal abnormalities (enlarged brain ventricle, decreased bone ossification and skeletal malformations) were observed starting at exposures below those in humans at the highest recommended dose of 300 mg, indicating potential clinical relevance.
In repeated dose toxicity studies, adverse effects were observed in reproductive organs, such as vaginal or uterine atrophy and oestrus cycle variations in rats, decreases in prostate and testes weight in rats and dogs and prostate atrophy in dogs at clinically relevant doses based on AUC.

In fertility studies conducted in male and female rats, similar effects on fertility were observed. In females, increased pre- and post-implantation losses, which led to reduced numbers of implantation sites and live embryos, were observed at exposure levels (AUC) approximately twice the recommended human dose of 300 mg. In males, fertility and reproductive performance, including sperm count and motility parameters, were unaffected at exposure levels approximately twice the estimated exposure (AUC) in humans at the recommended dose of 300 mg. However, at exposure levels (AUC) at or below the recommended human dose of 300 mg, accessory gland weights (seminal vesicles, prostate) were reduced and correlated microscopically with atrophy and/or reduced secretion in prostate and seminal vesicles, respectively.

**Phototoxicity**

An *in vitro* phototoxicity test on the mouse Balb/c 3T3 fibroblast cell line did not identify a relevant phototoxicity potential for alpelisib.

6. **PHARMACEUTICAL PARTICULARS**

6.1 **List of excipients**

**Tablet core**

Cellulose microcrystalline  
Mannitol  
Sodium starch glycolate  
Hypermellose  
Magnesium stearate

**Film coating**

Hypermellose  
Iron oxide, black (E172)  
Iron oxide, red (E172)  
Titanium dioxide (E171)  
Macrogol  
Talc

6.2 **Incompatibilities**

Not applicable.

6.3 **Shelf life**

3 years.

6.4 **Special precautions for storage**

This medical product does not require any special storage conditions.
6.5 Nature and contents of container

PVC/PCTFE/alu (polyvinylchloride/polychlorotrifluoroethylene/aluminium) blister sealed into a blister card containing 14 film-coated tablets.

Piqray 50 mg and 200 mg film-coated tablets

Packs containing 28 film-coated tablets (14 of 50 mg and 14 of 200 mg) or 56 film-coated tablets (28 of 50 mg and 28 of 200 mg).
Multipacks containing 168 film-coated tablets (3x 56, each comprising 28 tablets of 50 mg and 28 tablets of 200 mg).

Piqray 150 mg film-coated tablets

Packs containing 28 or 56 film-coated tablets.
Multipacks containing 168 (3x 56) film-coated tablets.

Piqray 200 mg film-coated tablets

Packs containing 14 or 28 film-coated tablets.
Multipacks containing 84 (3x 28) film-coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/20/1455/001-009

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

27 July 2020

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu
ANNEX II

A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers responsible for batch release

Novartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany

Lek Pharmaceuticals d.d.
Verovskova ulica 57
1526 Ljubljana
Slovenia

Novartis Pharmaceutical Manufacturing LLC
Verovskova ulica 57
1000 Ljubljana
Slovenia

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder (MAH) shall submit the first PSUR for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:
- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
• **Additional risk minimisation measures**

Prior to launch of Piqray in each Member State the Marketing Authorisation Holder (MAH) must agree about the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.

The educational programme is aimed at increasing awareness and providing information concerning the signs and symptoms of severe hyperglycaemia, including ketoacidosis, and how to manage them.

The MAH shall ensure that in each Member State where Piqray is marketed, all healthcare professionals who are expected to prescribe Piqray have access to/are provided with the physician educational material.

**The physician educational material** should contain:

- The Summary of Product Characteristics
- Guide for healthcare professionals

**The Guide for healthcare professionals** shall contain the following key elements:

Severe hyperglycaemia, in some cases associated with hyperglycaemic hyperosmolar nonketotic syndrome (HHNKS) or ketoacidosis, has been observed in patients treated with Piqray. Some cases of ketoacidosis with fatal outcome have been reported in the post marketing setting.

- **Prior to initiating treatment**
  - Piqray is associated with an increased risk of hyperglycaemia.
  - Patients at higher risk (diabetic, pre-diabetic, FPG \(\geq 250\) mg/dl, BMI \(\geq 30\), or age \(\geq 75\) years) need consultation with a healthcare professional experienced in the treatment of hyperglycaemia.
  - The patient’s current antidiabetic treatment might be affected by the treatment with alpelisib through interaction with oral antidiabetics metabolised by CYP2C9 and CYP2C8 (including, but not limited to, repaglinide, rosiglitazone, glipizide and tolbutamide).
  - Test for FPG and HbA1c and optimise the patient’s level of blood glucose before starting treatment with alpelisib.
  - Counsel patients with regard to the risk of hyperglycaemia, need for lifestyle changes, signs and symptoms of hyperglycaemia (e.g. excessive thirst, urinating more often than usual or greater amount of urine than usual, increased appetite with weight loss; difficulty breathing, headache, nausea, vomiting) and the importance of immediately contacting a healthcare professional if symptoms occur.

- **During treatment**
  - Follow the schedule for monitoring fasting glucose according to the Piqray label. Please note there are different schedules for patients with and without risk factors.
  - In case of hyperglycaemia follow the hyperglycaemia-related dose modification and management table according to the Piqray label.
  - When initiating antidiabetic treatment, consideration should be taken with regard to possible drug-drug interactions.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF PACKS CONTAINING 150 MG TABLETS

1. NAME OF THE MEDICINAL PRODUCT

Piqray 150 mg film-coated tablets
alpelisib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 150 mg alpelisib.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablet

28 tablets
14-day supply for a 300 mg daily dose.
56 tablets
28-day supply for a 300 mg daily dose.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/20/1455/001</td>
<td>28 film-coated tablets of 150 mg</td>
</tr>
<tr>
<td>EU/1/20/1455/002</td>
<td>56 film-coated tablets of 150 mg</td>
</tr>
</tbody>
</table>

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Piqray 150 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK CONTAINING 150 MG TABLETS (WITH BLUE BOX)

1. **NAME OF THE MEDICINAL PRODUCT**

   Piqray 150 mg film-coated tablets
   alpelisib

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each film-coated tablet contains 150 mg alpelisib.

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**

   Film-coated tablet

   Multipack: 168 (3x 56) tablets
   3x 28-day supply for a **300 mg daily dose**.

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Read the package leaflet before use.
   Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/20/1455/003 168 (3x 56) film-coated tablets of 150 mg

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Piqray 150 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING
INTERMEDIATE CARTON OF MULTIPACK CONTAINING 150 MG TABLETS (WITHOUT BLUE BOX)

<table>
<thead>
<tr>
<th><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Piqray 150 mg film-coated tablets alpelisib</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>2. STATEMENT OF ACTIVE SUBSTANCE(S)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Each film-coated tablet contains 150 mg alpelisib.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>3. LIST OF EXCIPIENTS</strong></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>4. PHARMACEUTICAL FORM AND CONTENTS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Film-coated tablet</td>
</tr>
<tr>
<td>56 tablets</td>
</tr>
<tr>
<td>28-day supply for a <strong>300 mg daily dose</strong></td>
</tr>
<tr>
<td>Component of a multipack. Not to be sold separately.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>5. METHOD AND ROUTE(S) OF ADMINISTRATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>Oral use</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>7. OTHER SPECIAL WARNING(S), IF NECESSARY</strong></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>8. EXPIRY DATE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>9. SPECIAL STORAGE CONDITIONS</strong></th>
</tr>
</thead>
</table>
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited  
Vista Building  
Elm Park, Merrion Road  
Dublin 4  
Ireland

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/20/1455/003  168 (3x 56) film-coated tablets of 150 mg

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Piqray 150 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**
**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**BLISTER CARD OF PACKS CONTAINING 150 MG TABLETS**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></td>
<td></td>
</tr>
<tr>
<td>Piqray 150 mg tablets</td>
<td>alpelisib</td>
</tr>
<tr>
<td><strong>2. NAME OF THE MARKETING AUTHORISATION HOLDER</strong></td>
<td></td>
</tr>
<tr>
<td>Novartis Europharm Limited</td>
<td></td>
</tr>
<tr>
<td><strong>3. EXPIRY DATE</strong></td>
<td></td>
</tr>
<tr>
<td>EXP</td>
<td></td>
</tr>
<tr>
<td><strong>4. BATCH NUMBER</strong></td>
<td></td>
</tr>
<tr>
<td>Lot</td>
<td></td>
</tr>
<tr>
<td><strong>5. OTHER</strong></td>
<td></td>
</tr>
<tr>
<td>Mon.</td>
<td>Tue.</td>
</tr>
<tr>
<td>Wed.</td>
<td>Thu.</td>
</tr>
<tr>
<td>Fri.</td>
<td>Sat.</td>
</tr>
<tr>
<td>Sun.</td>
<td></td>
</tr>
</tbody>
</table>

Take both tablets in the coloured row immediately after food on the day indicated.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF PACKS CONTAINING 200 MG TABLETS

1. NAME OF THE MEDICINAL PRODUCT

Piqray 200 mg film-coated tablets
alpelisib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 200 mg alpelisib.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablet

14 tablets
14-day supply for a 200 mg daily dose.
28 tablets
28-day supply for a 200 mg daily dose.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

- EU/1/20/1455/007  14 film-coated tablets of 200 mg
- EU/1/20/1455/008  28 film-coated tablets of 200 mg

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Piqray 200 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN
PARTICULARS TO APPEAR ON THE OUTER PACKAGING

OUTER CARTON OF MULTIPACK CONTAINING 200 MG TABLETS (WITH BLUE BOX)

1. NAME OF THE MEDICINAL PRODUCT

Piqray 200 mg film-coated tablets
alpelisib

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 200 mg alpelisib.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablet

Multipack: 84 (3x 28) tablets
3x 28-day supply for a 200 mg daily dose.

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS
### 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

### 11. NAME AND ADDRESS OF THE MARKETING AUTHORIZATION HOLDER

Novartis Europharm Limited  
Vista Building  
Elm Park, Merrion Road  
Dublin 4  
Ireland

### 12. MARKETING AUTHORIZATION NUMBER(S)

EU/1/20/1455/009  
84 (3x 28) film-coated tablets of 200 mg

### 13. BATCH NUMBER

Lot

### 14. GENERAL CLASSIFICATION FOR SUPPLY

### 15. INSTRUCTIONS ON USE

Piqray 200 mg

### 16. INFORMATION IN BRAILLE

### 17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

### 18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC  
SN  
NN
# PARTICULARS TO APPEAR ON THE OUTER PACKAGING

**INTERMEDIATE CARTON OF MULTIPACK CONTAINING 200 MG TABLETS (WITHOUT BLUE BOX)**

## 1. NAME OF THE MEDICINAL PRODUCT

Piqray 200 mg film-coated tablets
alpelisib

## 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 200 mg alpelisib.

## 3. LIST OF EXCIPIENTS

## 4. PHARMACEUTICAL FORM AND CONTENTS

Film-coated tablet

28 tablets
28-day supply for a **200 mg daily dose**.
Component of a multipack. Not to be sold separately.

## 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.
Oral use

## 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

## 7. OTHER SPECIAL WARNING(S), IF NECESSARY

## 8. EXPIRY DATE

EXP

## 9. SPECIAL STORAGE CONDITIONS
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited  
Vista Building  
Elm Park, Merrion Road  
Dublin 4  
Ireland

12. **MARKETING AUTHORISATION NUMBER(S)**

| EU/1/20/1455/009 | 84 (3x 28) film-coated tablets of 200 mg |

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Piqray 200 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**
### MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS

**BLISTER CARD OF PACKS CONTAINING 200 MG TABLETS**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Piqray 200 mg tablets</td>
</tr>
<tr>
<td>alpelisib</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novartis Europharm Limited</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mon.</td>
</tr>
<tr>
<td>Tue.</td>
</tr>
<tr>
<td>Wed.</td>
</tr>
<tr>
<td>Thu.</td>
</tr>
<tr>
<td>Fri.</td>
</tr>
<tr>
<td>Sat.</td>
</tr>
<tr>
<td>Sun.</td>
</tr>
</tbody>
</table>

Take one tablet immediately after food on the day indicated.
**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**OUTER CARTON OF PACKS CONTAINING 50 MG AND 200 MG TABLETS**

1. **NAME OF THE MEDICINAL PRODUCT**

Piqray 50 mg film-coated tablets
Piqray 200 mg film-coated tablets
alpelisib

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

Each film-coated tablet contains 50 mg or 200 mg alpelisib.

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**

Film-coated tablet

14 tablets of 50 mg
14 tablets of 200 mg
14-day supply for a **250 mg daily dose**.
28 tablets of 50 mg
28 tablets of 200 mg
28-day supply for a **250 mg daily dose**.

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.
Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

EXP

9. **SPECIAL STORAGE CONDITIONS**
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited  
Vista Building  
Elm Park, Merrion Road  
Dublin 4  
Ireland

12. **MARKETING AUTHORISATION NUMBER(S)**

<table>
<thead>
<tr>
<th>Number</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/20/1455/004</td>
<td>14 film-coated tablets of 50 mg + 14 film-coated tablets of 200 mg</td>
</tr>
<tr>
<td>EU/1/20/1455/005</td>
<td>28 film-coated tablets of 50 mg + 28 film-coated tablets of 200 mg</td>
</tr>
</tbody>
</table>

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Piqray 50 mg + 200 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN
**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

OUTER CARTON OF MULTIPACK CONTAINING 50 MG AND 200 MG TABLETS (WITH BLUE BOX)

---

1. **NAME OF THE MEDICINAL PRODUCT**

   Piqray 50 mg film-coated tablets  
   Piqray 200 mg film-coated tablets  
   alpelisib

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each film-coated tablet contains 50 mg or 200 mg alpelisib.

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**

   Film-coated tablet

   Multipack:  
   84 (3x28) tablets of 50 mg  
   84 (3x28) tablets of 200 mg  
   3x 28-day supply for a **250 mg daily dose**.

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Read the package leaflet before use.  
   Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**
<p>| 10. | SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE |
| 11. | NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER |
| Novartis Europharm Limited |
| Vista Building |
| Elm Park, Merrion Road |
| Dublin 4 |
| Ireland |
| 12. | MARKETING AUTHORISATION NUMBER(S) |
| EU/1/20/1455/006 |
| 84 (3x28) film-coated tablets of 50 mg + 84 (3x28) film-coated tablets of 200 mg |
| 13. | BATCH NUMBER |
| Lot |
| 14. | GENERAL CLASSIFICATION FOR SUPPLY |
| 15. | INSTRUCTIONS ON USE |
| 16. | INFORMATION IN BRAILLE |
| Piqray 50 mg + 200 mg |
| 17. | UNIQUE IDENTIFIER – 2D BARCODE |
| 2D barcode carrying the unique identifier included. |
| 18. | UNIQUE IDENTIFIER - HUMAN READABLE DATA |
| PC |
| SN |
| NN |</p>
<table>
<thead>
<tr>
<th>PARTICULARS TO APPEAR ON THE OUTER PACKAGING</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERMEDIATE CARTON OF MULTIPACK CONTAINING 50 MG AND 200 MG TABLETS (WITHOUT BLUE BOX)</td>
</tr>
</tbody>
</table>

1. **NAME OF THE MEDICINAL PRODUCT**

   Piqray 50 mg film-coated tablets  
   Piqray 200 mg film-coated tablets  
   alpelisib

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**

   Each film-coated tablet contains 50 mg or 200 mg alpelisib.

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**

   Film-coated tablet

   28 tablets of 50 mg  
   28 tablets of 200 mg  
   28-day supply for a 250 mg daily dose.  
   Component of a multipack. Not to be sold separately.

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**

   Read the package leaflet before use.  
   Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**

   EXP

9. **SPECIAL STORAGE CONDITIONS**
10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Novartis Europharm Limited  
Vista Building  
Elm Park, Merrion Road  
Dublin 4  
Ireland

12. **MARKETING AUTHORISATION NUMBER(S)**

EU/1/20/1455/006  
84 film-coated tablets of 50 mg + 84 film-coated tablets of 200 mg (3x 28 + 28)

13. **BATCH NUMBER**

Lot

14. **GENERAL CLASSIFICATION FOR SUPPLY**

15. **INSTRUCTIONS ON USE**

16. **INFORMATION IN BRAILLE**

Piqray 50 mg + 200 mg

17. **UNIQUE IDENTIFIER – 2D BARCODE**

18. **UNIQUE IDENTIFIER - HUMAN READABLE DATA**
### Minimum Particulars to Appear on Blisters or Strips
#### Blister Card of Packs Containing 50 mg and 200 mg Tablets

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td><strong>Name of the Medicinal Product</strong></td>
</tr>
</tbody>
</table>
|   | Piqray 50 mg tablets  
|   | Piqray 200 mg tablets  
|   | alpelisib |
| 2. | **Name of the Marketing Authorisation Holder** |
|   | Novartis Europharm Limited |
| 3. | **Expiry Date** |
|   | EXP |
| 4. | **Batch Number** |
|   | Lot |
| 5. | **Other** |
|   | Mon.  
|   | Tue.  
|   | Wed.  
|   | Thu.  
|   | Fri.  
|   | Sat.  
|   | Sun.  

Take both tablets in the coloured row immediately after food on the day indicated.
B. PACKAGE LEAFLET
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, or pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Piqray is and what it is used for
2. What you need to know before you take Piqray
3. How to take Piqray
4. Possible side effects
5. How to store Piqray
6. Contents of the pack and other information

1. What Piqray is and what it is used for

What Piqray is
Piqray contains the active substance alpelisib, which belongs to a group of medicines called phosphatidylinositol-3-kinase (PI3K) inhibitors.

What Piqray is used for
Piqray is used for the treatment of postmenopausal women, and men, with a type of breast cancer called advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Piqray is used in combination with fulvestrant, a hormonal anticancer therapy, in patients whose cancer has not responded to other hormonal treatments and who have certain changes (mutations) in a gene called PIK3CA.

Your doctor will take a sample of your blood and/or tumour tissue, which will be tested for these PIK3CA mutations. If the result is positive your cancer is likely to respond to treatment with Piqray.

How Piqray works
Piqray works by blocking the effects of enzymes called phosphatidylinositol-3-kinases (PI3K). These enzymes help cancer cells to grow and multiply. By blocking their action, Piqray can reduce growth and spread of the cancer and help to destroy cancer cells.

If you have any questions about how Piqray works or why this medicine has been prescribed for you, ask your doctor, pharmacist or nurse.
2. **What you need to know before you take Piqray**

Follow all of your doctor’s instructions carefully, as they may differ from the general information in this leaflet. Check with your doctor if you are not sure.

**Do not take Piqray:**
- if you are allergic to alpelisib or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice.

**Warnings and precautions**

Talk to your doctor or pharmacist before taking Piqray.

If any of the following apply to you before taking Piqray, tell your doctor or pharmacist:
- if you have or have ever had high levels of sugar in your blood or diabetes (or signs of increased sugar levels, such as excessive thirst and dry mouth, needing to pass urine more often than usual, producing greater amounts of urine than usual, tiredness, nausea, increased appetite with weight loss).
- if you have ever had Stevens-Johnson syndrome (SJS), erythema multiforme (EM), drug reaction with eosinophilia and systemic symptoms (DRESS) or toxic epidermal necrolysis (TEN; possible symptoms include red skin, blistering of the lips, eyes or mouth, skin peeling, with or without fever, rash).
- if you have a severe bone disease that affects the jaw (osteonecrosis of the jaw, ONJ).

If any of the following apply to you during your treatment with Piqray, tell your doctor or pharmacist immediately:
- Rash, itching, hives, breathlessness, difficulty breathing, wheezing, cough, light-headedness, dizziness, changes in levels of consciousness, low blood pressure, reddening of the skin, swelling of the face or throat, blue discoloration of the lips, tongue or skin (possible signs of severe allergic reactions).
- New or changing breathing problems such as difficult or painful breathing, cough, rapid breathing, blue discoloration of the lips, tongue or skin, hiccups (possible signs of non-infectious pneumonitis or pneumonia).
- Increased thirst and dry mouth, passing urine more often than usual, tiredness, increased appetite with weight loss, confusion, nausea, vomiting, fruity odour on breath, difficulty breathing and dry or flushed skin, which may be signs of increased blood sugar levels (hyperglycaemia) and its complications.
- Rash, reddening of the skin, blistering of the lips, eyes or mouth, skin peeling, sometimes with fever (possible signs of one of the following skin conditions: Stevens-Johnson syndrome (SJS), erythema multiforme (EM), drug reaction with eosinophilia and systemic symptoms (DRESS) or toxic epidermal necrolysis (TEN)).
- New or worsening symptoms affecting your mouth (such as loose teeth, pain or swelling, non-healing of mouth sores, or discharge).
- Severe diarrhoea or severe abdominal pain or stools with mucus or blood, which may be signs of inflammation of your intestine (colitis).

Your doctor may need to treat these symptoms, temporarily interrupt your treatment, reduce your dose, or permanently stop your treatment with Piqray.

**Blood tests before and during your treatment with Piqray**

Your doctor will carry out blood tests before and regularly during treatment with Piqray to monitor your blood sugar. Based on the results, your doctor will take any necessary actions, such as prescribing a medicine to lower blood sugar levels. If necessary, your doctor may decide to temporarily interrupt treatment with Piqray or reduce your Piqray dose to allow your blood sugar to decrease. Your doctor may also decide to stop Piqray treatment permanently.
Make sure that you regularly test your blood sugar before you start treatment, during treatment and after you stop treatment with Piqray.

- Your doctor will tell you exactly when and where to have the blood tests. Treatment with Piqray may only be started if tests show that you have the right levels of sugar in your blood. This is because Piqray can increase sugar in your blood (hyperglycaemia), which could be serious and need treatment. Only regular fasting blood tests can tell the doctor if you are developing hyperglycaemia.
- Your doctor will tell you exactly when and where to test your blood sugar. This will be required more frequently in the first 4 weeks of treatment and especially in the first 2 weeks of treatment with Piqray. Afterwards, blood tests will be needed at least once a month, depending on your blood sugar levels.

**Children and adolescents**

Piqray is not to be used in children and adolescents under 18 years of age.

**Other medicines and Piqray**

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes in particular:
- eltrombopag, a medicine used to treat low platelet count
- medicines used to treat breast cancer, such as lapatinib, everolimus or ribociclib
- pantoprazole, a medicine used to treat heartburn and reduce the amount of acid produced in your stomach
- midazolam, a medicine used to for sedation or sleep disturbances
- rifampicin, a medicine to treat tuberculosis and some other serious infections
- encorafenib, a medicine used to treat a certain type of skin cancer
- warfarin, a medicine used reduce the clotting ability of the blood

Ask your doctor or pharmacist if you are not sure whether your medicine is one of the medicines listed above.

**Pregnancy, breast-feeding and fertility**

Piqray must not be used by women who are, or may be pregnant or breast-feeding. Piqray may harm an unborn baby. If you think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Women should not breast-feed during treatment and for at least 1 week after the last dose of Piqray. Your doctor will discuss with you the potential risks of taking Piqray during pregnancy or breast-feeding.

If you are a woman who could become pregnant, your doctor will rule out an existing pregnancy before starting you on treatment with Piqray. This may include having a pregnancy test.

Women who could become pregnant should use an effective method of birth control during treatment and for at least 1 week after stopping Piqray. Ask your doctor about suitable methods. If you think you may be pregnant after starting treatment with Piqray, tell your doctor immediately.

During treatment and for at least 1 week after stopping treatment, male patients should use a condom for intercourse with female partners who could become pregnant. If the partner of a male patient suspects that she has become pregnant during this time, she should inform a doctor immediately.

**Driving and using machines**

Treatment with Piqray may lead to tiredness. You should therefore be cautious when driving or using machines during your treatment with Piqray.

**Piqray contains sodium**

This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially ‘sodium-free’.
3. **How to take Piqray**

Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.

**How much Piqray to take**
The usual starting dose of Piqray is 300 mg once daily. Your doctor will decide on the right dose for you.

Depending on the dose prescribed, the number of tablets to take is as follows:
- 300 mg dose: two 150 mg tablets
- 250 mg dose: one 200 mg tablet and one 50 mg tablet
- 200 mg dose: one 200 mg tablet

If you vomit after you take the Piqray tablet(s), do not take any more tablets until your next scheduled dose.

Your doctor will determine the dose of fulvestrant you should receive and when you should receive it.

Depending on how your body responds to the treatment with Piqray, your doctor may want to adjust your Piqray dose. It is very important to follow your doctor’s instructions. If you have certain side effects, your doctor may ask you to change to a lower dose, to interrupt treatment for a time, or to stop treatment.

**When to take Piqray**
Piqray tablets are supplied in packs containing blister cards. Each blister card shows the tablet(s) to be taken on each day of the week. Follow the instructions on the blister card.

Take Piqray once a day, immediately after food. Taking Piqray at the same time each day will help you to remember when to take your medicine.

**How to take Piqray**
Piqray tablets should be swallowed whole, they should not be chewed, crushed or split before swallowing. You should not swallow any tablet that is broken, cracked or otherwise damaged as you may not be taking the full dose.

**How long to take Piqray**
Take Piqray for as long as your doctor tells you to.

This is a long-term treatment, possibly lasting for months or years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect.

If you have questions about how long to take Piqray, talk to your doctor or to your pharmacist.

**If you take more Piqray than you should**
People who have taken too many Piqray tablets have experienced effects that are known side effects of Piqray, including high blood sugar levels, nausea, tiredness and rash. If you accidentally take too many tablets, or if someone else accidentally takes your medicine, contact a doctor or hospital for advice immediately. Medical treatment may be necessary.

**If you forget to take Piqray**
If you forget to take a dose of Piqray, you may still take it, immediately after food, up to 9 hours after the time you should have taken it. If you only remember more than 9 hours after you should have taken it, skip the dose for that day. The next day, take the dose at your usual time. Do not take a double dose to make up for the one that you missed.
If you stop taking Piqray
Stopping your treatment with Piqray may cause your condition to become worse. Do not stop taking Piqray unless your doctor tells you to stop.

If you have any further questions on the use of Piqray, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some side effects could be serious
If you get any serious side effects, stop taking this medicine and tell your doctor immediately.

Very common: may affect more than 1 in 10 people
- Feeling very thirsty, passing urine more often than usual or passing greater amounts of urine than usual, increased appetite with weight loss (possible symptoms of high blood sugar levels, also called hyperglycaemia)
- Fever, cough, runny nose, enlarged lymph nodes, painful joints, rash, night sweats, weight loss (possible symptoms of a low level of lymphocytes, a type of white blood cells)

Common: may affect up to 1 in every 10 people
- Rash, itching, hives, breathlessness, difficulty breathing, wheezing, cough, light-headedness, dizziness, changes in levels of consciousness, low blood pressure, reddening of the skin, swelling of the face and/or throat, blue discoloration of the lips, tongue or skin (possible signs of severe allergic reactions)
- Breathing problems including difficult or painful breathing, cough, rapid breathing, blue discoloration of the lips, tongue or skin, hiccups (possible symptoms of pneumonitis)
- Passing urine less often than usual or passing smaller amounts of urine than usual, swelling in legs, ankles and around the eyes, tiredness, confusion, nausea, seizure, chest pain (possible symptoms of acute kidney failure)
- Pain, swelling or numbness of the jaw, a feeling of heaviness in the jaw or loosening of a tooth (possible symptoms of osteonecrosis of the jaw)
- Rash, skin reddening, blistering of lips, eyes or mouth, skin peeling (possible symptoms of erythema multiforme)

Uncommon: may affect up to 1 in every 100 people
- Difficulty breathing, headache, nausea, vomiting (possible symptoms of a condition called ketoacidosis that involves a high level of acids in the blood)
- Severe upper stomach pain (possible symptoms of pancreatitis)
- Rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever (possible symptoms of Stevens-Johnson syndrome)

Not known: frequency cannot be estimated from the available data
- Diarrhoea, an increased number of bowel movements than usual, blood in your stools or darker-coloured stools, pain or tenderness in your stomach area (possible symptoms of colitis, inflammation of the intestines).
- Confusion, dry mouth, dry or flushed skin, nausea, vomiting, tiredness, need to pass urine frequently, thirst (possible symptoms of hyperglycaemic hyperosmolar nonketotic syndrome (HHNKs))
- Swelling of your face or throat and difficulty breathing (possible symptoms of angioedema, a type of severe allergic reaction).
- Rash, fever (possible symptoms of drug rash with eosinophilia and systemic symptoms (DRESS))
Other possible side effects

Other side effects include the following listed below. If these side effects become severe, tell your doctor, pharmacist or nurse.

**Very common:**
- Painful and frequent urination (possible symptoms of urinary tract infection)
- Tiredness, pale skin (possible symptoms of anaemia, a condition involving a low level of red blood cells)
- Spontaneous bleeding or bruising (signs of a low level of thrombocytes, also called platelets, in the blood)
- Loss of appetite
- Headache
- Strange taste in the mouth (dysgeusia)
- Diarrhoea
- Nausea
- Vomiting
- Mouth sores or ulcers with gum inflammation (stomatitis)
- Abdominal pain
- Upset stomach, indigestion (dyspepsia)
- Rash
- Hair loss or hair thinning (alopecia)
- Itching (pruritus)
- Dry skin
- Tiredness (fatigue)
- Pain, redness and swelling of airways or food pipe or genital mucosa (mucosal inflammation)
- Swollen hands, ankles or feet (peripheral oedema)
- Fever (pyrexia)
- Mucosal dryness
- Weight decreased
- Reduced level of calcium in the blood, which may sometimes lead to cramps (hypocalcaemia)
- Reduced level of potassium in the blood, associated with muscle weakness, muscle spasms and/or abnormal heart rhythm (hypokalaemia)

**Common:**
- Dehydration
- Problems falling asleep (insomnia)
- Dry eye
- Blurred vision
- Headache, dizziness (possible symptoms of high blood pressure)
- Swelling of part or all of your arm (including fingers) or leg (including toes), feeling of heaviness, restricted movement, discomfort, thickening of the skin and recurring infections (possible symptoms of lymphoedema)
- Toothache
- Bleeding, tender or enlarged gums (signs of inflammation of the gums)
- Cracked, chapped lips (cheilitis)
- Gingival pain
- Erythema
- Skin inflammation with rash (dermatitis)
- Reddening and/or swelling and possibly peeling on the palms of the hands and soles of the feet, which may be accompanied by a tingling sensation and burning pain (signs of hand-foot syndrome)
- Muscle spasms
- Muscle pain (myalgia)
- Generalised swelling (oedema)
During Piqray treatment, the results of some blood tests may be abnormal, as follows:

**Very common:**
- High blood levels of the following enzymes: gamma glutamyl transferase, alanine aminotransferase, lipase
- High blood level of sugar
- High blood level of creatinine and/or calcium
- Low blood level of lymphocytes, platelets, sugar, haemoglobin and/or albumin
- Increase in activated partial thromboplastin time (a measurement of blood clotting ability)

**Common:**
- High blood level of glycosylated haemoglobin (a marker of blood sugar level over the last 8 to 12 weeks)

**Reporting of side effects**
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Piqray**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and the blister card after “EXP”. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Do not take this medicine if you notice any damage to the packaging or if there are any signs of tampering.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Piqray contains**
- The active substance of Piqray is alpelisib.
- Each 50 mg Piqray film-coated tablet contains 50 mg alpelisib.
- Each 150 mg Piqray film-coated tablet contains 150 mg alpelisib.
- Each 200 mg Piqray film-coated tablet contains 200 mg alpelisib.
- The other ingredients are:
  - Tablet core: cellulose microcrystalline, mannitol, sodium starch glycolate, hypromellose, magnesium stearate.
  - Coating material: Hypromellose, iron oxide red and black (E172), titanium dioxide (E171), Macrogol, talc.
What Piqray looks like and contents of the pack

Piqray 50 mg film-coated tablets are light pink, round tablets, imprinted with “L7” on one side and “NVR” on the other side. Approximate diameter: 7.2 mm.

Piqray 150 mg film-coated tablets are pale red, ovaloid tablets, imprinted with “UL7” on one side and “NVR” on the other side. Approximate size: 14.2 mm (length); 5.7 mm (width).

Piqray 200 mg film-coated tablets are light red, ovaloid tablets, imprinted with “YL7” on one side and “NVR” on the other side. Approximate size: 16.2 mm (length); 6.5 mm (width).

Piqray is supplied as film-coated tablets in blisters. Piqray is available in the following pack sizes:
- Packs containing 50 mg and 200 mg film-coated tablets (for patients on 250 mg daily dose):
  - Packs containing 14-day supply: 28 film-coated tablets (14 of 50 mg and 14 of 200 mg).
  - Packs containing 28-day supply: 56 film-coated tablets (28 of 50 mg and 28 of 200 mg).
  - Multipacks containing 168 film-coated tablets (3x 56, each comprising 28 tablets of 50 mg and 28 tablets of 200 mg).
- Packs containing 150 mg film-coated tablets (for patients on 300 mg daily dose)
  - Packs containing 14-day supply: 28 film-coated tablets.
  - Packs containing 28-day supply: 56 film-coated tablets.
  - Multipacks containing 168 (3x 56) film-coated tablets.
- Packs containing 200 mg film-coated tablets (for patients on 200 mg daily dose)
  - Packs containing 14-day supply: 14 film-coated tablets.
  - Packs containing 28-day supply: 28 film-coated tablets.
  - Multipacks containing 84 (3x 28) film-coated tablets.

Not all pack sizes may be marketed.

Marketing Authorisation Holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland

Manufacturer
Novartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany

Lek Pharmaceuticals d.d.
Verovskova ulica 57
1526 Ljubljana
Slovenia

Novartis Pharmaceutical Manufacturing LLC
Verovskova ulica 57
1000 Ljubljana
Slovenia
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

**България**
Novartis Bulgaria EOOD
Tel: +359 2 489 98 28

**Česká republika**
Novartis s.r.o.
Tel: +420 225 775 111

**Danmark**
Novartis Healthcare A/S
Tlf: +45 39 16 84 00

**Deutschland**
Novartis Pharma GmbH
Tel: +49 911 273 0

**Eesti**
SIA Novartis Baltics Eesti filiaal
Tel: +372 66 30 810

**Ελλάδα**
Novartis (Hellas) A.E.B.E.
Τηλ.: +30 210 281 17 12

**España**
Novartis Farmacéutica, S.A.
Tel: +34 93 306 42 00

**France**
Novartis Pharma S.A.S.
Tél: +33 1 55 47 66 00

**Hrvatska**
Novartis Hrvatska d.o.o.
Tel: +385 1 6274 220

**Ireland**
Novartis Ireland Limited
Tel: +353 1 260 12 55

**Ísland**
Vistor hf.
Sími: +354 535 7000

**Italia**
Novartis Farma S.p.A.
Tel: +39 02 96 54 1

**Italian**
Novartis Farma S.p.A.
Tel: +39 02 96 54 1

**Lietuva**
SIA Novartis Baltics Lietuvos filialas
Tel: +370 5 269 16 50

**Luxembourg/Luxemburg**
Novartis Pharma N.V.
Tél/Tel: +32 2 246 16 11

**Magyarország**
Novartis Hungária Kft.
Tel.: +36 1 457 65 00

**Malta**
Novartis Pharma Services Inc.
Tel: +356 2122 2872

**Nederland**
Novartis Pharma B.V.
Tel: +31 88 04 52 555

**Norge**
Novartis Norge AS
Tlf: +47 23 05 20 00

**Österreich**
Novartis Pharma GmbH
Tel: +43 1 86 6570

**Polska**
Novartis Poland Sp. z o.o.
Tel.: +48 22 375 4888

**Portugal**
Novartis Farma - Produtos Farmacêuticos, S.A.
Tel: +351 21 000 8600

**România**
Novartis Pharma Services Romania SRL
Tel: +40 21 31299 01

**Slovenija**
Novartis Pharma Services Inc.
Tel: +386 1 300 75 50

**Slovenská republika**
Novartis Slovakia s.r.o.
Tel: +421 2 5542 5439

**Suomi/Finland**
Novartis Finland Oy
Puh/Tel: +358 (0)10 6133 200
This leaflet was last revised in

Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu